BAX Stock Cash Flow Statements

Baxter International Quarterly Cash Flow Statements Chart

Quarterly

Annual

Capital Expenditure

Baxter International Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30	2008-03-31	2007-09-30	2007-06-30	2007-03-31	2006-09-30	2006-06-30	2006-03-31	2005-09-30	2005-06-30	2005-03-31	2004-09-30	2004-06-30	2004-03-31

cash flows from operations		-193,000,000	488,000,000	253,000,000	115,000,000	163,000,000	531,000,000	365,000,000	351,000,000	479,000,000	439,000,000	290,000,000	274,000,000	208,000,000	693,000,000	675,000,000	477,000,000	377,000,000	712,000,000	510,000,000	374,000,000	272,000,000	829,000,000	664,000,000	264,000,000	347,000,000		544,000,000	343,000,000	389,000,000		251,000,000	265,000,000	272,000,000		130,000,000	1,212,000,000	3,380,000,000		1,000,000	332,000,000	430,000,000		468,000,000	520,000,000	556,000,000		544,000,000	590,000,000	552,000,000		583,000,000	661,000,000	588,000,000	532,000,000	589,000,000	518,000,000										-114,000,000	554,000,000	224,000,000			-55,000,000
net income	91,000,000	126,000,000	-510,000,000	144,000,000	-311,000,000	39,000,000	246,000,000	2,511,000,000	-139,000,000	45,000,000	185,000,000	-2,934,000,000	255,000,000	73,000,000	242,000,000	452,000,000	301,000,000	300,000,000	171,000,000	359,000,000	247,000,000	333,000,000	-19,000,000	340,000,000
less: income from discontinued operations, net of tax	-31,000,000	62,000,000	-22,000,000				173,000,000	2,460,000,000
income from continuing operations	122,000,000	64,000,000	-488,000,000	434,000,000	-311,000,000	39,000,000	73,000,000	51,000,000																																																																189,000,000
adjustments to reconcile net income to cash flows from operations:
depreciation and amortization	257,000,000	247,000,000	245,000,000	129,000,000	288,000,000	335,000,000	324,000,000	311,000,000	309,000,000	319,000,000	334,000,000	334,000,000	355,000,000	380,000,000	245,000,000	206,000,000	222,000,000	217,000,000	213,000,000	209,000,000	202,000,000	199,000,000	209,000,000	187,000,000																																																148,000,000
deferred income taxes	-23,000,000	-142,000,000	-126,000,000	-1,000,000	-66,000,000	-69,000,000	98,000,000	-441,000,000	-106,000,000	-50,000,000	-51,000,000	-87,000,000	-32,000,000	-55,000,000	-48,000,000	-62,000,000	-11,000,000	-25,000,000	-43,000,000	-22,000,000	-6,000,000	-17,000,000	-265,000,000	10,000,000																																																10,000,000
stock compensation	35,000,000	10,000,000	39,000,000	22,000,000	28,000,000	25,000,000	30,000,000	41,000,000	37,000,000	25,000,000	32,000,000	45,000,000	45,000,000	32,000,000	53,000,000	34,000,000	37,000,000	22,000,000	33,000,000	33,000,000	35,000,000	29,000,000	30,000,000	35,000,000
net periodic pension and other postretirement costs	-8,000,000	-8,000,000	-7,000,000	-10,000,000	-6,000,000	-5,000,000	-7,000,000	-4,000,000	-4,000,000	-4,000,000		14,000,000	14,000,000	14,000,000		26,000,000	25,000,000	26,000,000
other long-lived asset impairments	2,000,000	22,000,000	2,000,000	31,000,000			9,000,000
other	14,000,000	6,000,000	21,000,000	-4,000,000	15,000,000	9,000,000	32,000,000	14,000,000	17,000,000	14,000,000	23,000,000	6,000,000	-29,000,000	-12,000,000	46,000,000	36,000,000	-4,000,000	14,000,000	32,000,000	27,000,000	14,000,000	13,000,000	25,000,000	69,000,000																																																23,000,000
changes in balance sheet items:
accounts receivable	-66,000,000	26,000,000	-18,000,000	6,000,000	-160,000,000	137,000,000	-121,000,000	-47,000,000	-34,000,000	136,000,000	-30,000,000	-159,000,000	-110,000,000	153,000,000	-42,000,000	-86,000,000	-93,000,000	51,000,000	0	-101,000,000	35,000,000	-60,000,000	-42,000,000																																																	-99,000,000
inventories	-157,000,000	-122,000,000	-21,000,000	49,000,000	-25,000,000	-204,000,000	102,000,000	-7,000,000	-28,000,000	-181,000,000	49,000,000	-102,000,000	-203,000,000	-105,000,000	112,000,000	6,000,000	-26,000,000	-129,000,000	143,000,000	-44,000,000	-178,000,000	-83,000,000	92,000,000	3,000,000																																																-68,000,000
prepaid expenses and other current assets	34,000,000	-24,000,000	-64,000,000	-17,000,000	-34,000,000	-10,000,000	4,000,000	-5,000,000	0	-39,000,000	59,000,000	-31,000,000	-54,000,000	-13,000,000	10,000,000	-27,000,000	-26,000,000	2,000,000
accounts payable	5,000,000	16,000,000	109,000,000	-61,000,000	-67,000,000	131,000,000	-29,000,000	-21,000,000	0	157,000,000	-160,000,000	-7,000,000	86,000,000	5,000,000	90,000,000	23,000,000	-31,000,000	22,000,000
accrued expenses and other current liabilities	-8,000,000	-143,000,000	236,000,000	-27,000,000	25,000,000	-190,000,000	40,000,000	212,000,000	67,000,000	93,000,000	-23,000,000	-19,000,000	-10,000,000	-221,000,000	17,000,000	100,000,000	115,000,000	-124,000,000
cash flows from (used in) operations - continuing operations
cash flows from (used in) operations - discontinued operations
cash flows from (used in) operations
cash flows from investing activities		3,265,000,000	-205,000,000	-164,000,000	-91,000,000	-166,000,000	-230,000,000	3,786,000,000	-173,000,000	-170,000,000	-256,000,000	-184,000,000	-187,000,000	-304,000,000	-10,267,000,000	-207,000,000	-188,000,000	-538,000,000	-264,000,000	-157,000,000	-154,000,000	-604,000,000	-421,000,000	-217,000,000	-264,000,000	-198,000,000		-157,000,000	-156,000,000	-155,000,000		-131,000,000	-156,000,000	-123,000,000		-167,000,000	-168,000,000	-184,000,000		363,000,000	-500,000,000	-521,000,000	-573,000,000	-481,000,000	-423,000,000	-421,000,000	-488,000,000	-398,000,000	-347,000,000	-292,000,000	-399,000,000	-259,000,000	-264,000,000	-239,000,000	-247,000,000	-216,000,000	-171,000,000	-251,000,000	-207,000,000	-157,000,000	-166,000,000	-165,000,000	-93,000,000	-138,000,000	-122,000,000	-76,000,000	-165,000,000					-77,000,000
capital expenditures	-140,000,000	-122,000,000	-132,000,000	-22,000,000	-116,000,000	-176,000,000	-190,000,000	-174,000,000	-156,000,000	-172,000,000	-200,000,000	-168,000,000	-171,000,000	-140,000,000	-235,000,000	-179,000,000	-158,000,000	-171,000,000	-237,000,000	-156,000,000	-144,000,000	-172,000,000	-191,000,000	-153,000,000																																																-89,000,000
free cash flows
acquisitions of developed technology and investments			-5,000,000	-2,000,000	-1,000,000	-6,000,000
proceeds from sale of marketable equity securities			0	0	18,000,000	16,000,000
other investing activities	34,000,000	-2,000,000	8,000,000	0			7,000,000	14,000,000	0	5,000,000	1,000,000	0	0	10,000,000	7,000,000	18,000,000	6,000,000	14,000,000	1,000,000	12,000,000	0	11,000,000	2,000,000	11,000,000
cash flows from (used in) investing activities - continuing operations
cash flows from (used in) investing activities - discontinued operations
cash flows from (used in) investing activities
cash flows from financing activities		-3,226,000,000	141,000,000	-146,000,000	-936,000,000	-140,000,000	-2,935,000,000	-62,000,000	-120,000,000	-372,000,000	-119,000,000	-302,000,000	-469,000,000	-548,000,000	9,276,000,000	-324,000,000	-349,000,000	-358,000,000	-1,143,000,000	-111,000,000	-261,000,000	1,170,000,000	-116,000,000	-354,000,000	173,000,000	795,000,000				-87,000,000		0				1,580,000,000	0	61,000,000		121,000,000	5,847,000,000	900,000,000		7,000,000	2,000,000	32,000,000		9,000,000	3,481,000,000	8,000,000		1,010,000,000	0	12,000,000	501,000,000	3,000,000	358,000,000	9,000,000	505,000,000	4,000,000	16,000,000	42,000,000	15,000,000	624,000,000	8,000,000	75,000,000	411,000,000	-379,000,000	20,000,000			-150,000,000
repayments of debt	-680,000,000	-2,825,000,000	-1,830,000,000	-3,000,000	-809,000,000	-15,000,000	-2,281,000,000	-211,000,000	-139,000,000	-3,000,000	-1,000,000	-204,000,000	-345,000,000	-404,000,000	-2,416,000,000
repayments of debt with original maturities of three months or less
cash dividends on common stock	-87,000,000	-87,000,000	-147,000,000	-148,000,000	-148,000,000	-147,000,000	-147,000,000	-147,000,000	-146,000,000	-146,000,000	-146,000,000	-146,000,000	-141,000,000	-140,000,000	-140,000,000	-141,000,000	-124,000,000	-125,000,000	-125,000,000	-125,000,000	-112,000,000	-111,000,000	-113,000,000	-112,000,000
proceeds from stock issued under employee benefit plans	6,000,000	10,000,000	8,000,000	11,000,000	12,000,000	40,000,000	9,000,000	32,000,000	18,000,000	36,000,000	13,000,000	26,000,000	22,000,000	66,000,000	52,000,000	42,000,000	45,000,000	48,000,000	22,000,000	29,000,000	85,000,000	66,000,000	22,000,000	72,000,000																																																31,000,000
other financing activities	-1,000,000	-24,000,000	-16,000,000	-6,000,000	9,000,000	-18,000,000	-3,000,000	-1,000,000	-51,000,000	-10,000,000	-10,000,000	-21,000,000	-5,000,000	-25,000,000	-7,000,000	4,000,000	-9,000,000	-28,000,000	-4,000,000	-14,000,000	-9,000,000	-25,000,000	-6,000,000	-5,000,000
cash flows from (used in) financing activities
effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - continuing operations	52,000,000	36,000,000
increase in cash, cash equivalents and restricted cash	-608,000,000	-118,000,000	334,000,000	-16,000,000			-2,594,000,000								-305,000,000	121,000,000	-46,000,000	-550,000,000	-630,000,000	272,000,000
cash, cash equivalents and restricted cash at beginning of period	0	2,414,000,000		0	0	3,198,000,000		0	0	1,722,000,000		0	0	2,956,000,000		0	0	3,736,000,000		0
cash, cash equivalents and restricted cash at end of period	-608,000,000	2,296,000,000		-16,000,000	-934,000,000	3,030,000,000		4,066,000,000	49,000,000	1,677,000,000		-252,000,000	-443,000,000	2,299,000,000		121,000,000	-46,000,000	3,186,000,000		272,000,000
less cash and cash equivalents of discontinued operations			-10,000,000
cash, cash equivalents and restricted cash of continuing operations	-608,000,000	2,296,000,000	344,000,000
cash and cash equivalents	-608,000,000	2,294,000,000	344,000,000	-675,000,000	-931,000,000	3,026,000,000	-2,594,000,000	4,066,000,000	49,000,000	1,673,000,000		-251,000,000	-442,000,000	2,294,000,000		122,000,000	-46,000,000	3,182,000,000		274,000,000
restricted cash included in other non-current assets	0	2,000,000		1,000,000	-3,000,000	4,000,000
cash and cash equivalents of discontinued operations
cash, cash equivalents and restricted cash	-608,000,000	2,296,000,000	344,000,000	-674,000,000	-934,000,000	3,030,000,000	-2,594,000,000	4,066,000,000	49,000,000	1,677,000,000		-252,000,000	-443,000,000	2,299,000,000		121,000,000	-46,000,000	3,186,000,000		272,000,000
cash flows from operations - continuing operations		-99,000,000		98,000,000	115,000,000	163,000,000		317,000,000
cash flows from operations - discontinued operations		-94,000,000						48,000,000
cash flows from investing activities - continuing operations		-124,000,000	-129,000,000	-24,000,000	-91,000,000	-166,000,000	-183,000,000	-163,000,000
cash flows from investing activities - discontinued operations		3,389,000,000	-76,000,000				-47,000,000	3,949,000,000
net decreases in debt with original maturities of three months or less		-300,000,000							198,000,000	-249,000,000				-45,000,000						-1,000,000
pension settlement and curtailment (gains) losses
goodwill impairments											27,000,000
intangible asset impairments							0				12,000,000								0	0
loss on product divestiture arrangement											0
reclassification of cumulative translation loss to earnings											0
loss on subsidiary liquidation
cash flows from operations – continuing operations															693,000,000	675,000,000	477,000,000	377,000,000	712,000,000	510,000,000	374,000,000	274,000,000	829,000,000	664,000,000
cash flows from operations – discontinued operations																			0	0	0	-2,000,000	0	0
increase in short term debt
net (decreases) increases in debt with original maturities of three months or less
purchases of treasury stock											0				0	-35,000,000	-312,000,000	-253,000,000					-241,000,000	-309,000,000																																																-11,000,000
effect of foreign exchange rate changes on cash, cash equivalents and restricted cash					-22,000,000	-25,000,000	40,000,000	-23,000,000	-9,000,000	18,000,000	54,000,000	-56,000,000	-61,000,000	-13,000,000	-7,000,000	-23,000,000	14,000,000	-31,000,000	65,000,000	30,000,000
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
as of december 31
restricted cash included in prepaid expenses and other current assets							0	0	0	4,000,000		-1,000,000	-1,000,000	5,000,000		-1,000,000	0	4,000,000		-2,000,000
net increases in debt with original maturities of three months or less
effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - discontinued operations
goodwill impairment
decrease in cash, cash equivalents and restricted cash						-168,000,000			49,000,000	-45,000,000		-252,000,000	-443,000,000	-657,000,000
adjustments to reconcile net income to cash flows operations:
losses on debt extinguishments
acquisitions, net of cash acquired, and investments							0	-3,000,000	0	-3,000,000	-57,000,000	-16,000,000	-16,000,000	-174,000,000	-10,039,000,000	-46,000,000	-36,000,000	-381,000,000		-13,000,000
issuances of debt															11,853,000,000					0	0	1,240,000,000		0																																																87,000,000
debt issuance costs															-61,000,000
property, plant and equipment impairments
adjustments to reconcile net income to net cash from operating activities:
net periodic pension benefit and other postretirement costs																					20,000,000	20,000,000	14,000,000	1,000,000
settlement of interest rate derivative contracts
net increase in debt with original maturities of three months or less															-5,000,000	200,000,000
net increases (decreases) in debt with original maturities of three months or less												75,000,000
pension settlement charges
loss on debt extinguishment
intangible asset impairment																							0	0
adjustments to reconcile income from continuing operations to net cash from operating activities:
income from discontinued operations, net of tax
accounts payable and accrued liabilities																			107,000,000	84,000,000	62,000,000	-110,000,000	37,000,000	59,000,000																																																-196,000,000
acquisitions and investments, net of cash acquired																						-443,000,000
issuances of long-term debt
payments of long-term debt
(repayments) borrowings under revolving credit facility
effect of foreign exchange rate changes on cash and cash equivalents																						-63,000,000	34,000,000	-15,000,000	-26,000,000	2,000,000
increase in cash and cash equivalents																						775,000,000	326,000,000	78,000,000	1,017,000,000	76,000,000
cash and cash equivalents at beginning of period																						3,335,000,000		6,000,000	0	1,832,000,000
cash and cash equivalents at end of period																						4,110,000,000		84,000,000	1,017,000,000	1,908,000,000
balance at beginning of period																						112,000,000
adoption of new accounting standard																						4,000,000
charged to costs and expenses																						7,000,000
currency translation adjustments																						-9,000,000
balance at end of period																						114,000,000
borrowings under revolving credit facility
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
other supplemental information
interest paid, net of portion capitalized
income taxes paid																																			47,000,000	108,000,000	-84,000,000	429,000,000
acquisitions and investments																								-75,000,000
baxter international inc.
condensed consolidated balance sheet
current assets:
total current assets
property, plant and equipment
goodwill
other intangible assets
other non-current assets
total assets
current liabilities:
short-term debt
current maturities of long-term debt and finance lease obligations
total current liabilities
long-term debt and finance lease obligations
other non-current liabilities
total liabilities
commitments and contingencies
equity:
common stock, 1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares
common stock in treasury, at cost, 170,495,859 shares
additional contributed capital
retained earnings
accumulated other comprehensive income
total baxter stockholders’ equity
noncontrolling interests
total equity
total liabilities and equity
restructuring charges
accounts and other current receivables
restructuring payments																																																																								-37,000,000
non-cash investing and financing activities
decrease in liabilities for capital expenditures																									-10,000,000	57,000,000
decrease in liability for treasury stock purchases																									12,000,000	11,000,000
supplemental schedule of non-cash activities
cash flows from																																																																						259,000,000
operations
investing activities																																																																						0
financing activities																																																																						-259,000,000
supplemental schedule of non-cash investing and financing activities
net proceeds on retained shares transactions
payment of obligations in exchange for retained shares																																			0	0	0	3,646,000,000
exchange of baxter shares with retained shares																																			0	0
(increases) decreases in the accrual for capital expenditures
effect of foreign exchange rate changes on cash and equivalents																												-23,000,000	-67,000,000	25,000,000	-85,000,000	45,000,000	23,000,000	22,000,000	-50,000,000	6,000,000	-5,000,000	22,000,000	-21,000,000	-41,000,000	-28,000,000	-105,000,000	-24,000,000	-28,000,000	-20,000,000	-7,000,000
increase in cash and equivalents																												3,000,000	-90,000,000	-447,000,000	-123,000,000	-300,000,000			204,000,000	-33,000,000											357,000,000	-3,613,000,000			79,000,000										-668,000,000	102,000,000	-101,000,000	1,006,000,000	180,000,000	40,000,000	284,000,000					-279,000,000
cash and equivalents at beginning of period																												0	0	3,394,000,000		0	0	2,801,000,000		0	0	2,213,000,000		0	0	2,925,000,000		0	0	2,733,000,000		0	0	3,270,000,000		0	0	2,905,000,000	0	0	2,131,000,000	0	0	2,539,000,000	0	0	2,485,000,000	0	0	841,000,000	0	0	1,109,000,000	0	-2,000,000	927,000,000
cash and equivalents at end of period																												3,000,000	-90,000,000	2,947,000,000		-300,000,000	959,000,000	2,858,000,000		-33,000,000	419,000,000	2,211,000,000		-4,710,000,000	4,150,000,000	2,530,000,000		212,000,000	-183,000,000	2,049,000,000		-3,613,000,000	3,300,000,000	2,689,000,000		838,000,000	81,000,000	2,272,000,000	769,000,000	99,000,000	1,703,000,000	44,000,000	411,000,000	1,736,000,000	-668,000,000	102,000,000	2,384,000,000	1,006,000,000	180,000,000	881,000,000	284,000,000	322,000,000	1,106,000,000	62,000,000	112,000,000	648,000,000
cost of sales
gross margin
marketing and administrative expenses
research and development expenses
operating income
other income
cash and equivalents at beginning of year
cash and equivalents at end of year
as of and for the years ended december 31
common stock
balance, beginning and end of year
common stock in treasury
beginning of year
purchases of common stock
stock issued under employee benefit plans and other
end of year
dividends declared on common stock
stock issued under employee benefit plans
distribution of baxalta
other comprehensive income
total baxter shareholders’ equity
change in noncontrolling interests
net proceeds on the baxalta retained share transactions
payment of obligations in exchange for baxalta retained shares
exchange of baxter shares with baxalta retained shares
major classes of line items constituting income from discontinued operations before income taxes
net sales
income from discontinued operations before income taxes
gain on disposal of discontinued operations
income tax expense
other income and expense items that are not major
decrease in cash and equivalents																																		57,000,000				-2,000,000				-395,000,000				-684,000,000				-581,000,000			81,000,000	-633,000,000		99,000,000	-428,000,000			-803,000,000										62,000,000
net proceeds on retained share transactions																																				0	1,148,000,000	3,239,000,000
total income from discontinued operations before income taxes
total income from discontinued operations
exercise of sigma purchase option
balance, beginning of year and end of period
end of period
accumulated other comprehensive loss
income before income taxes
income tax (benefit) expense
elimination of sigma noncontrolling ownership interest
interest expense, net of capitalized interest																																																																		41,000,000
interest income																																																																		-10,000,000
net interest expense																																																																		31,000,000
cash flows
from operations
net income attributable to baxter
other comprehensive income attributable to baxter
effect of currency exchange rate changes on cash and equivalents																																																0	9,000,000	-18,000,000		-6,000,000	-36,000,000	2,000,000	31,000,000	-2,000,000	-76,000,000	-20,000,000	-12,000,000	50,000,000	7,000,000	-35,000,000	-9,000,000	-5,000,000	-34,000,000	-31,000,000	-13,000,000	-5,000,000	19,000,000	-26,000,000	10,000,000	3,000,000
other comprehensive loss attributable to baxter
raw materials
work in process
finished goods
property, plant and equipment, at cost
accumulated depreciation and amortization
property, plant and equipment (pp&e)
pension benefits
service cost																																																																	-1,000,000	21,000,000
interest cost																																																																	-1,000,000	41,000,000
expected return on plan assets																																																																	1,000,000	-43,000,000
amortization of net incomees and other deferred amounts
net periodic pension benefit cost
opeb
amortization of prior service credit and net income
net periodic opeb cost
net pension plan expense																																																																	-1,000,000	40,000,000
net opeb plan expense																																																																	-4,000,000	13,000,000
cash flows from operating activities																																																										472,000,000	544,000,000	429,000,000	395,000,000	431,000,000	403,000,000	374,000,000	309,000,000	282,000,000
amortization of net income, prior service cost and transition obligation																																																																	0	21,000,000
amortization of net income and prior service cost																																																																	-2,000,000	3,000,000
net interest expense consisted of the following.
net income, as reported																																																																				146,000,000	176,000,000	218,000,000	-143,000,000	178,000,000
add:
stock-based employee compensation expense included in reported net income, net of tax
deduct:
total stock-based employee compensation expense determined under the fair value method, net of tax																																																																						13,000,000
pro forma net income																																																																				158,000,000	148,000,000	232,000,000	-163,000,000	150,000,000
earnings per basic share
as reported																																																																				230,000	290,000	370,000	-230,000	290,000
pro forma																																																																				240,000	250,000	400,000	-270,000	250,000
earnings per diluted share
adjustments
restructuring
infusion pump charge
changes in balance sheet items
cash flows from continuing operations																																																																								-54,000,000
cash flows from discontinued operations																																																																								-1,000,000
acquisitions (net of cash received) and investments in and advances to affiliates																																																																								-14,000,000
divestitures and other																																																																								26,000,000
payments of obligations
increase in debt with maturities of three months or less																																																																								137,000,000
common stock cash dividends																																																																								-361,000,000
add: stock-based employee compensation expense included in reported net income, net of tax
deduct: total stock-based employee compensation expense determined under the fair value method, net of tax																																																																					28,000,000			28,000,000
contributions to pension trust																																																																								-54,000,000
redemptions of debt and lease obligations																																																																								-33,000,000
from investing
activities
from financing
supplemental schedule of non-cash investing activities
fair value of assets acquired, net of liabilities assumed
common stock issued at fair value
net cash paid

We provide you with 20 years of cash flow statements for Baxter International stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Baxter International stock. Explore the full financial landscape of Baxter International stock with our expertly curated income statements.

The information provided in this report about Baxter International stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.